Explanations for the difference in rates of cardiovascular events in a trial of alendronate and romosozumab

被引:45
作者
Cummings, S. R. [1 ,2 ]
McCulloch, C. [2 ]
机构
[1] Pacific Med Ctr, Res Inst, San Francisco Coordinating Ctr Calif, Box 0560,550-16th St,2nd Floor, San Francisco, CA 94143 USA
[2] Univ Calif San Francisco, Dept Epidemiol & Biostat, Div Biostat, San Francisco, CA 94115 USA
关键词
FRACTURE PREVENTION; WOMEN;
D O I
10.1007/s00198-020-05379-z
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
[No abstract available]
引用
收藏
页码:1019 / 1021
页数:3
相关论文
共 8 条
[1]   Romosozumab Treatment in Postmenopausal Women with Osteoporosis [J].
Cosman, F. ;
Crittenden, D. B. ;
Adachi, J. D. ;
Binkley, N. ;
Czerwinski, E. ;
Ferrari, S. ;
Hofbauer, L. C. ;
Lau, E. ;
Lewiecki, E. M. ;
Miyauchi, A. ;
Zerbini, C. A. F. ;
Milmont, C. E. ;
Chen, L. ;
Maddox, J. ;
Meisner, P. D. ;
Libanati, C. ;
Grauer, A. .
NEW ENGLAND JOURNAL OF MEDICINE, 2016, 375 (16) :1532-1543
[2]  
Fayers PM, 1997, STAT MED, V16, P1413, DOI 10.1002/(SICI)1097-0258(19970630)16:12<1413::AID-SIM578>3.0.CO
[3]  
2-U
[4]   Bisphosphonates for cardiovascular risk reduction: A systematic review and meta-analysis [J].
Kranenburg, Guido ;
Bartstra, Jonas W. ;
Weijmans, Maaike ;
de Jong, Pim A. ;
Mali, Willem P. ;
Verhaar, Harald J. ;
Visseren, Frank L. J. ;
Spiering, Wilko .
ATHEROSCLEROSIS, 2016, 252 :106-115
[5]   Fracture Prevention with Zoledronate in Older Women with Osteopenia [J].
Reid, Ian R. ;
Horne, Anne M. ;
Mihov, Borislav ;
Stewart, Angela ;
Garratt, Elizabeth ;
Wong, Sumwai ;
Wiessing, Katy R. ;
Bolland, Mark J. ;
Bastin, Sonja ;
Gamble, Gregory D. .
NEW ENGLAND JOURNAL OF MEDICINE, 2018, 379 (25) :2407-2416
[6]   Romosozumab or Alendronate for Fracture Prevention in Women with Osteoporosis [J].
Saag, Kenneth G. ;
Petersen, Jeffrey ;
Brandi, Maria Luisa ;
Karaplis, Andrew C. ;
Lorentzon, Mattias ;
Thomas, Thierry ;
Maddox, Judy ;
Fan, Michelle ;
Meisner, Paul D. ;
Grauer, Andreas .
NEW ENGLAND JOURNAL OF MEDICINE, 2017, 377 (15) :1417-1427
[7]  
U.S. Food and Drug Administration, 2019, FDA BRIEF INF DOC M, P35
[8]  
U.S. Food and Drug Administration Amgen Inc., 2019, AMG PRES CARD SAF M